《藍籌業績》中生製藥(01177.HK)上半年純利19.2億人幣按年跌77.3% 中期息增至6港仙
中國生物製藥(01177.HK)公布截至今年6月底止中期業績,營業額151.94億元人民幣(下同),按年升5.9%。純利19.21億元,按年跌77.3%;每股盈利10.3分。派中期息6港仙,上年同期派4港仙。
期內,毛利為122.3億元,按年增5.5%。扣除應佔聯營及一家合營盈利及虧損(扣除相關稅項及非控制權益),若干非現金項目及一次性調整後,經調整非《香港財務報告準則》淨利潤為16.6億元,按年增4.5%。
按業務劃分,上半年五年內上市的新產品收入為66.1億元,按年增24.6%,佔收入比例由36.9%升至43.5%;抗腫瘤用藥收入49.6億元,按年升16.7%,佔收入32.6%;創新藥收入按年增14.2%至34.9億元,佔收入22.9%。
於上半年,研發總開支約由去年同期的18.8億元增至21.9億元,佔集團收入約14.4%。截至6月底,集團累計有臨床批件、正在進行臨床試驗和申報生產的在研產品共418件,其中肝病用藥29件、抗腫瘤用藥230件、呼吸系統用藥31件等。
集團指,其持股15.03%、主要從事人用疫苗研發、生產和銷售的科興中維開發的新冠疫苗「克爾來福」,目前已累計在62個國家、地區和國際組織獲批使用,全球供應總量超28億劑。但隨著市場環境不斷變化,其新冠疫苖銷量下降,財務表現低於去年同期,使得集團應佔聯營及一家合營盈虧於回顧期內減少至約5.03億元,扣除相關稅項及非控制權益約3,466萬元後,實質盈利貢獻共約4.69億元。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.